ADCT · ADC Therapeutics SA
$1.10
-0.01 (-0.90%)
At close · Jul 29
Market Cap
$141.18M
Shares
127.19M
ADC Therapeutics SA Earnings Call Transcripts
Every quarterly earnings call for ADC Therapeutics SA (ADCT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$18.05M
−$46.61M
'24 Q1
24-05-06
·
$17.41M
−$36.54M
'24 Q2
24-08-06
·
$18.46M
−$43.97M
'24 Q3
24-11-07
·
$16.91M
−$30.68M
'24 Q4
25-01-13
▲27.6%
$23.03M
−$38.60M
'25 Q1
25-05-14
▲8.2%
$18.84M
−$56.65M
'25 Q2
25-08-12
▼11%
$16.43M
−$40.97M
'25 Q3
25-11-03
▲36.4%
$23.06M
−$6.39M
'25 Q4
26-03-10
LATEST
▼9.5%
$20.85M
−$32.97M
'26 Q1
26-05-04
Earnings call
FY26 · Q1
2026-05-04
ADC Therapeutics SA Q1 FY2026 Earnings Call
Positive tone
ZYNLONTA Commercial Performance
LOTIS-5 Confirmatory Trial
Cost Management and Cash Runway
Revenue
$20.85M
▼ 9.5% YoY Diluted EPS
$-0.21
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-10
ADC Therapeutics SA Q4 FY2025 Earnings Call
Confident tone
LOTIS-5 trial and 2L expansion
ZYNLONTA commercial performance in 3L+ DLBCL
Indolent lymphoma opportunity
Revenue
$23.06M*
▲ 36.4% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
ADC Therapeutics SA Q3 FY2025 Earnings Call
Positive tone
LOTUS V Phase III confirmatory trial
ZENLATA commercial performance and stability
DLBCL treatment landscape segmentation
Revenue
$16.43M
▼ 11% YoY Diluted EPS
$-0.30
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
ADC Therapeutics SA Q2 FY2025 Earnings Call
Confident tone
LOTIS-7 bispecific combination data
ZYNLONTA commercial performance
LOTIS-5 confirmatory Phase 3
Revenue
$18.84M
▲ 8.2% YoY Diluted EPS
$-0.50
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
ADC Therapeutics SA Q1 FY2025 Earnings Call
Positive tone
LOTIS-7 ZYNLONTA plus glofitamab combination
Upcoming medical congress data presentations
ZYNLONTA commercial performance and 3L+ DLBCL positioning
Revenue
$23.03M
▲ 27.6% YoY Diluted EPS
$-0.36
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
ADC Therapeutics SA Q4 FY2024 Earnings Call
Confident tone
ZYNLONTA Commercial Performance
LOTIS-5 Phase 3 Trial
Indolent Lymphoma Expansion (FL/MZL)
Revenue
$16.91M*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
ADC Therapeutics SA Q3 FY2024 Earnings Call
Positive tone
ZYNLONTA commercial performance and DLBCL positioning
LOTIS-7 ZYNLONTA plus glofitamab combination
LOTIS-5 Phase III confirmatory study
Revenue
$18.46M
Diluted EPS
$-0.42
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
ADC Therapeutics SA Q2 FY2024 Earnings Call
Positive tone
ZYNLONTA commercial performance
Hematology pipeline expansion
Solid tumor pipeline
Revenue
$17.41M
Diluted EPS
$-0.38
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
ADC Therapeutics SA Q1 FY2024 Earnings Call
Confident tone
ZYNLONTA commercial performance
LOTIS-7 ZYNLONTA plus bispecifics
LOTIS-5 Phase 3 confirmatory study
Revenue
$18.05M
Diluted EPS
$-0.56
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-04
ADC Therapeutics SA Q4 FY2023 Earnings Call
Positive tone
ZYNLONTA commercial performance
Pipeline expansion and earlier-line opportunities
Competitive landscape and bispecifics
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
ADC Therapeutics SA Q3 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
ADC Therapeutics SA Q2 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
ADC Therapeutics SA Q1 FY2023 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
ADC Therapeutics SA Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
ADC Therapeutics SA Q3 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
ADC Therapeutics SA Q2 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
ADC Therapeutics SA Q1 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
ADC Therapeutics SA Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-09-30
ADC Therapeutics SA Q3 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
ADC Therapeutics SA Q2 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
ADC Therapeutics SA Q1 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
ADC Therapeutics SA Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
ADC Therapeutics SA Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
ADC Therapeutics SA Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts
CIK
1771910
CUSIP
H0036K147
13F (30d)
16 filings
16 filers
Visit website
Investor relations